NASDAQ:ORIC ORIC Pharmaceuticals (ORIC) Stock Forecast, Price & News $5.84 -0.05 (-0.85%) (As of 10:21 AM ET) Add Compare Share Share Today's Range$5.64▼$5.9150-Day Range$5.89▼$9.2852-Week Range$2.36▼$9.79Volume229,555 shsAverage Volume308,459 shsMarket Capitalization$318.46 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability ORIC Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside154.7% Upside$15.00 Price TargetShort InterestBearish19.65% of Float Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment1.13Based on 2 Articles This WeekInsider TradingSelling Shares$118,900 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.96) to ($2.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector454th out of 975 stocksPharmaceutical Preparations Industry201st out of 455 stocks 3.5 Analyst's Opinion Consensus RatingORIC Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, ORIC Pharmaceuticals has a forecasted upside of 154.7% from its current price of $5.89.Amount of Analyst CoverageORIC Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted19.65% of the float of ORIC Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverORIC Pharmaceuticals has a short interest ratio ("days to cover") of 18.1, which indicates bearish sentiment.Change versus previous monthShort interest in ORIC Pharmaceuticals has recently increased by 2.13%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldORIC Pharmaceuticals does not currently pay a dividend.Dividend GrowthORIC Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreORIC Pharmaceuticals has received a 77.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for ORIC Pharmaceuticals is -0.59. Previous Next 4.0 News and Social Media Coverage News SentimentORIC Pharmaceuticals has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ORIC Pharmaceuticals this week, compared to 1 article on an average week.Search Interest5 people have searched for ORIC on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows4 people have added ORIC Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ORIC Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $118,900.00 in company stock.Percentage Held by InsidersOnly 5.34% of the stock of ORIC Pharmaceuticals is held by insiders.Percentage Held by Institutions91.30% of the stock of ORIC Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ORIC Pharmaceuticals are expected to decrease in the coming year, from ($1.96) to ($2.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ORIC Pharmaceuticals is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ORIC Pharmaceuticals is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioORIC Pharmaceuticals has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ORIC Pharmaceuticals (NASDAQ:ORIC) StockORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Read More ORIC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORIC Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comNextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhDSeptember 23, 2023 | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated at WedbushOctober 3, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 20, 2023 | benzinga.comORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare ConferenceSeptember 20, 2023 | finance.yahoo.comORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare ConferenceSeptember 13, 2023 | msn.comNavigating ORIC's Robust Strategy Against Cancer Drug ResistanceAugust 17, 2023 | markets.businessinsider.comOric Pharmaceuticals (ORIC) Receives a Buy from Robert W. BairdAugust 16, 2023 | msn.comBaird Maintains ORIC Pharmaceuticals (ORIC) Outperform RecommendationOctober 3, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 15, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)August 11, 2023 | msn.comMarkets Today: Stocks Fall on a Hot U.S. July PPIAugust 11, 2023 | msn.comORIC Pharmaceuticals GAAP EPS of -$0.50 beats by $0.08August 11, 2023 | finance.yahoo.comORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational UpdatesAugust 4, 2023 | finance.yahoo.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 28, 2023 | markets.businessinsider.comWhy Oric Pharmaceuticals Stock Is Shooting Higher TodayJune 26, 2023 | finance.yahoo.comWhy Shares of Oric Pharmaceuticals Jumped MondayJune 26, 2023 | seekingalpha.comORIC Pharmaceuticals launches ~$85M private placement of shares, warrantsJune 26, 2023 | markets.businessinsider.comORIC Pharma Surges On $85 Mln Private Placement FinancingJune 26, 2023 | finance.yahoo.comORIC Pharmaceuticals Announces $85 Million Private Placement FinancingJune 8, 2023 | msn.comHC Wainwright & Co. Reiterates ORIC Pharmaceuticals (ORIC) Buy RecommendationMay 31, 2023 | finance.yahoo.comORIC Pharmaceuticals to Participate in the Jefferies Healthcare ConferenceMay 12, 2023 | msn.comHC Wainwright & Co. Maintains ORIC Pharmaceuticals (ORIC) Buy RecommendationMay 8, 2023 | msn.comORIC Pharmaceuticals GAAP EPS of -$0.53May 8, 2023 | finance.yahoo.comORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational UpdatesMay 5, 2023 | finance.yahoo.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 25, 2023 | finance.yahoo.comORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor ConferenceApril 18, 2023 | finance.yahoo.comORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual MeetingSee More Headlines Receive ORIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ORIC Company Calendar Last Earnings8/10/2023Today10/02/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORIC CUSIPN/A CIK1796280 Webwww.oricpharma.com Phone650-388-5600FaxN/AEmployees89Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$27.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+154.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-40.74% Return on Assets-36.89% Debt Debt-to-Equity RatioN/A Current Ratio18.46 Quick Ratio18.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.62 per share Price / Book1.05Miscellaneous Outstanding Shares54,530,000Free Float51,621,000Market Cap$321.18 million OptionableNot Optionable Beta0.92 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Richard A. Heyman Ph.D. (Age 66)Co-Founder, Independent Chairman & Member of Scientific Advisory Board Comp: $93kDr. Jacob M. Chacko M.B.A. (Age 44)M.D., Pres, CEO & Director Comp: $921.32kMr. Dominic G. Piscitelli CPA (Age 48)CPA, M.B.A., Chief Financial Officer Comp: $636.91kDr. Pratik S. Multani M.D. (Age 56)M.S., Chief Medical Officer Comp: $686.88kDr. Charles L. Sawyers B.A. (Age 64)BA, M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Scott W. Lowe Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Lori Sickels Friedman Ph.D. (Age 59)Chief Scientific Officer Dr. Christian V. Kuhlen Esq. (Age 50)J.D., M.D., Gen. Counsel Mr. Daniel IazzettiVP & Head of PeopleDr. Edna Chow Maneval (Age 63)Sr. VP of Clinical Devel. More ExecutivesKey CompetitorsLyell ImmunopharmaNASDAQ:LYELEdgewise TherapeuticsNASDAQ:EWTXMarinus PharmaceuticalsNASDAQ:MRNSAerovate TherapeuticsNASDAQ:AVTEUroGen PharmaNASDAQ:URGNView All CompetitorsInsiders & InstitutionsBarclays PLCBought 7,772 shares on 9/21/2023Ownership: 0.014%California State Teachers Retirement SystemBought 12,984 shares on 8/21/2023Ownership: 0.024%Wells Fargo & Company MNBought 14,600 shares on 8/15/2023Ownership: 0.030%Royal Bank of CanadaBought 4,065 shares on 8/15/2023Ownership: 0.007%Citadel Advisors LLCSold 5,600 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ORIC Stock - Frequently Asked Questions Should I buy or sell ORIC Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORIC shares. View ORIC analyst ratings or view top-rated stocks. What is ORIC Pharmaceuticals' stock price forecast for 2023? 7 brokerages have issued 12 month price targets for ORIC Pharmaceuticals' shares. Their ORIC share price forecasts range from $8.00 to $27.00. On average, they anticipate the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 154.7% from the stock's current price. View analysts price targets for ORIC or view top-rated stocks among Wall Street analysts. How have ORIC shares performed in 2023? ORIC Pharmaceuticals' stock was trading at $5.89 at the beginning of the year. Since then, ORIC stock has increased by 0.0% and is now trading at $5.89. View the best growth stocks for 2023 here. When is ORIC Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our ORIC earnings forecast. How were ORIC Pharmaceuticals' earnings last quarter? ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its earnings results on Thursday, August, 10th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.08. What other stocks do shareholders of ORIC Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG). When did ORIC Pharmaceuticals IPO? (ORIC) raised $75 million in an initial public offering (IPO) on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO. What is ORIC Pharmaceuticals' stock symbol? ORIC Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORIC." How do I buy shares of ORIC Pharmaceuticals? Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ORIC Pharmaceuticals' stock price today? One share of ORIC stock can currently be purchased for approximately $5.89. How much money does ORIC Pharmaceuticals make? ORIC Pharmaceuticals (NASDAQ:ORIC) has a market capitalization of $321.18 million. The company earns $-89,120,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. How can I contact ORIC Pharmaceuticals? ORIC Pharmaceuticals' mailing address is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.oricpharma.com. The company can be reached via phone at 650-388-5600 or via email at investors@oricpharma.com. This page (NASDAQ:ORIC) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.